Benzinga | Jan 5, 2021 04:07PM EST

REGENXBIO Says Pivotal Program For RGX-314 In Treatment Of Wet AMD Is Now Active; Co. Also Announces RGX-202 Program In Duchenne Muscular Dystrophy

ROCKVILLE, Md., Jan. 5, 2021 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today provided an update on the RGX-314 programs, including the announcement that the pivotal program for RGX-314 for the treatment of wet age-related macular degeneration (wet AMD) is now active. In addition, REGENXBIO announced a new program, RGX-202, a novel, potentially best-in-class, one-time gene therapy for the treatment of Duchenne Muscular Dystrophy (DMD).